INAB IN8bio, Inc. - Common Stock
NASDAQ · Biotechnology · 在 SEC EDGAR 上查看 ↗ 收盘 十月 2, 2026 10-K/10-Q 八月 6, 2026
$1.40
· % 处于52周区间
· 高于低点
· 至高点
$0.8852周低点
$2.7252周高点
市值 (MRQ)
$14M
P/E
-0.3
EPS
$-4.44
INAB 股票快照 价格、市值、P/E、EPS、ROE、负债/权益、52周范围
价格
$1.40
市值 (MRQ)
$14M
P/E
-0.3
EPS
$-4.44
ROE
-90.8%
52周区间
$1–$3
INAB 股价图表 包含技术指标的日 OHLCV — 平移、缩放和自定义您的视图
区间
条形图
柱状图粒度会根据所选周期进行调整 — 将鼠标悬停在图表上可查看柱状图的开盘价/最高价/最低价/收盘价。
股票拆分
| 除息日 | 拆股 | 类型 |
|---|---|---|
| 2025年6月6日 | 1-for-30 | 反向 |
10年表现 收入、净利润、利润率和每股收益趋势
EPS$-4.442021-12-31 → 2025-12-31
估值与比率
估值 P/E、P/S、P/B、EV/EBITDA 比率 — 该股票是昂贵还是便宜？
| 指标 | 5年趋势 | INAB | 5年均值 | 同行中位数 | 结论 |
|---|---|---|---|---|---|
| P/E | -0.35年均值 ≈-36.6 | ≈-36.6 | · | · | |
| 市净率 (MRQ) | 0.85年均值 ≈53.1 | ≈53.1 | 1.3 | 低估 | |
| Price / Cash Flow (市现率) | -1.15年均值 ≈-83.0 | ≈-83.0 | · | · | |
| Price / Tangible Book (市净率（有形资产）) | 0.55年均值 ≈46.5 | ≈46.5 | · | · |
同行中位数按每项指标的标准化基础计算，可能与本股票显示的TTM/MRQ基础不完全匹配。
盈利能力 毛利率、营业利润率和净利率；股本回报率 (ROE)、资产回报率 (ROA)、投入资本回报率 (ROIC)
| 指标 | 5年趋势 | INAB | 5年均值 | 同行中位数 | 结论 |
|---|---|---|---|---|---|
| ROA | -73.0%5年均值 ≈-71.3% | ≈-71.3% | -89.9% | 顶尖 | |
| ROE | -90.8%5年均值 ≈-94.1% | ≈-94.1% | -136.8% | 顶尖 | |
| ROIC | -70.5% | · | · | · |
财务健康 债务、流动性、偿付能力 — 资产负债表强度
| 指标 | 5年趋势 | INAB | 5年均值 | 同行中位数 | 结论 |
|---|---|---|---|---|---|
| 流动比率 (MRQ) | 8.25年均值 ≈8.6 | ≈8.6 | 3.7 | 流动性强 | |
| Quick Ratio (速动比率) | 8.65年均值 ≈8.0 | ≈8.0 | 3.5 | 流动性强 |
成长 营收、每股收益 (EPS) 和净利润增长：同比、3年复合年增长率 (CAGR)、5年复合年增长率 (CAGR)
此比率组尚无数据
基本面数据不足，尚无法计算此比率组。
资本效率 资产周转率、库存周转率、应收账款周转率
此比率组尚无数据
基本面数据不足，尚无法计算此比率组。
价值 · ≈ 5年均值 · 行业中值 · 相对于中值的评判
收益历史 每股收益实际值 vs 预估值，惊喜%，达标率，下次财报日期
平均惊喜
31.3%
下次报告
十一月 04, 2026
| 期间 | 报告 | EPS Actual | EPS 预期 | 惊喜 |
|---|---|---|---|---|
| 2026年6月30日 | 八月 5, 2026 | $-0.25 | $-0.38 | 34.3% |
| 2026年3月31日 | $-0.26 | $-0.70 | 63.1% | |
| 2025年12月31日 | $-0.45 | $-0.63 | 28.5% | |
| 2025年9月30日 | $-0.85 | $-1.25 | 32.2% | |
| 2025年6月30日 | $-1.24 | $-1.84 | 32.5% | |
| 2025年3月31日 | $-2.10 | $-2.04 | -2.9% |
完整基本面 所有年度指标 — 损益表、资产负债表、现金流量表
损益表
| 指标 | 趋势 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
| R&D Expense | $10M | $17M | $17M | $14M | $7M | $5M | |
| SG&A Expense | $10M | $13M | $14M | $14M | $7M | $3M | |
| Operating Expenses | $20M | $31M | $30M | $29M | $15M | $9M | |
| Operating Income | $-19M | $-30M | $-30M | $-29M | $-15M | $-9M | |
| Interest Income | $421.0K | $230.0K | $0 | · | · | · | |
| Pretax Income | $-19M | $-31M | · | · | · | · | |
| Income Tax | $0 | $0 | $0 | $0 | $0 | $0 | |
| Net Income | $-19M | $-30M | $-30M | $-29M | $-15M | $-9M | |
| EPS (Basic) | $-4.44 | $-17.05 | $-1.00 | $-1.36 | $-1.47 | · | |
| EPS (Diluted) | $-4.44 | $-17.05 | $-1.00 | $-1.36 | $-1.47 | · | |
| Shares (Basic) | 4,374,328 | 1,784,890 | 29,864,932 | 20,967,955 | 9,969,733 | · | |
| Shares (Diluted) | 4,374,328 | 1,784,890 | 29,864,932 | 20,967,955 | 9,969,733 | · | |
| EBITDA | $-19M | · | $-30M | $-29M | $-15M | · |
资产负债表
| 指标 | 趋势 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $27M | $11M | $21M | $18M | $37M | $18M | |
| Prepaid Expense | $788.0K | $1M | $3M | $4M | $2M | $150.0K | |
| Other Current Assets | $259.0K | $298.0K | $270.0K | $232.0K | $52.0K | $0 | |
| Current Assets | $28M | $13M | $25M | $22M | $39M | $18M | |
| PP&E (Net) | $2M | $3M | $4M | $4M | $97.0K | $186.0K | |
| PP&E (Gross) | · | · | · | · | $443.0K | $443.0K | |
| Accum. Depreciation | $3M | $2M | $1M | $321.0K | $346.0K | $257.0K | |
| Other Non-current Assets | $146.0K | $275.0K | $255.0K | $255.0K | $158.0K | $0 | |
| Total Assets | $32M | $21M | $34M | $33M | $42M | $21M | |
| Accounts Payable | $309.0K | $389.0K | $924.0K | $2M | $395.0K | $620.0K | |
| Accrued Liabilities | $2M | $1M | $3M | $2M | $1M | $2M | |
| Current Liabilities | $3M | $3M | $5M | $6M | $2M | $3M | |
| Capital Leases | $2M | $3M | $3M | $4M | $2M | $0 | |
| Total Liabilities | $5M | $6M | $9M | $10M | $4M | $3M | |
| Common Stock | $10.0K | $7.0K | $4.0K | $3.0K | $2.0K | $1.0K | |
| Paid-in Capital | $169M | $136M | $116M | $84M | $71M | $1M | |
| Retained Earnings | $-141M | $-122M | $-91M | $-61M | $-33M | $-18M | |
| Stockholders' Equity | $28M | $14M | $25M | $23M | $-38M | $-17M | |
| Liabilities + Equity | $32M | $21M | $34M | $33M | $42M | $21M | |
| Shares Outstanding | 9,766,132 | 2,416,066 | 43,287,325 | 24,545,157 | 18,781,242 | 3,764,488 |
现金流
| 指标 | 趋势 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
| Stock-based Comp | $3M | $5M | $4M | $3M | $2M | $357.0K | |
| Deferred Tax | $-2M | $-6M | $-6M | $-5M | $-5M | $-3M | |
| Operating Cash Flow | $-13M | $-24M | $-23M | $-24M | $-14M | $-7M | |
| Investing Cash Flow | $0 | $-187.0K | $-600.0K | $-4M | $-309.0K | $0 | |
| Stock Issued | $9M | $4M | $14M | $10M | $36M | $499.0K | |
| Net Stock Activity | $9M | · | $14M | $10M | $36M | · | |
| Financing Cash Flow | $29M | $14M | $27M | $9M | $33M | $25M | |
| Net Change in Cash | $16M | $-10M | $3M | $-19M | $19M | $17M |
盈利能力
| 指标 | 趋势 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
| ROA | -73.0% | · | -89.9% | -75.8% | -46.4% | · | |
| ROE | -90.8% | · | -140.6% | -109.1% | -36.1% | · | |
| ROIC | -70.5% | · | · | · | · | · |
流动性与偿付能力
| 指标 | 趋势 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
| Current Ratio | 8.8 | · | 4.6 | 3.8 | 17.3 | · | |
| Quick Ratio | 8.6 | · | 3.9 | 3.1 | 16.4 | · |
每股
| 指标 | 趋势 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
| Book Value / Share | $2.82 | · | $0.58 | $0.93 | $2.03 | · | |
| Cash Flow / Share | $-2.91 | · | $-0.78 | $-1.15 | · | · | |
| Cash / Share | $2.77 | · | $0.49 | $0.74 | $1.97 | · | |
| EPS (TTM) | $-4.44 | $-17.05 | $-1.00 | $-1.36 | $-1.47 | · |
估值 (TTM)
| 指标 | 趋势 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
| Net Income TTM | $-19M | $-30M | $-30M | $-29M | $-15M | · | |
| Market Cap | $23M | · | $1.79B | $1.70B | $2.47B | · | |
| P/E | -0.5 | -0.5 | -41.4 | -51.0 | -89.6 | · | |
| P/B | 0.8 | · | 71.9 | 74.8 | 64.8 | · | |
| P / Tangible Book | 0.8 | 38.6 | 71.9 | 74.8 | · | · | |
| P / Cash Flow | -1.8 | · | -76.8 | -70.5 | -183.1 | · | |
| Earnings Yield | -189.7% | -221.1% | -2.4% | -2.0% | -1.1% | · |
损益表
| 指标 | 趋势 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| R&D Expense | $2M | $3M | $3M | $2M | $2M | $3M | $4M | $3M | $5M | $5M | $5M | $4M | $4M | $4M | $4M | $4M | |
| SG&A Expense | $2M | $3M | $2M | $2M | $3M | $3M | $3M | $3M | $4M | $4M | $3M | $3M | $4M | $3M | $4M | $3M | |
| Operating Expenses | $5M | $5M | $5M | $4M | $5M | $6M | $6M | $7M | $9M | $9M | $8M | $7M | $8M | $8M | $8M | $7M | |
| Operating Income | $-5M | $-5M | $-5M | $-4M | $-5M | $-6M | $-6M | $-7M | $-9M | $-9M | $-8M | $-7M | $-8M | $-8M | $-8M | $-7M | |
| Interest Income | $154.0K | $176.0K | $91.0K | $113.0K | $107.0K | $110.0K | $64.0K | $23.0K | $60.0K | $83.0K | $0 | $0 | $0 | $0 | · | · | |
| Net Income | $-5M | $-5M | $-5M | $-4M | $-5M | $-6M | $-6M | $-7M | $-9M | $-9M | $-8M | $-7M | $-8M | $-8M | $-8M | $-7M | |
| EPS (Basic) | $-0.25 | $-0.26 | $-2.28 | $-0.85 | $-1.24 | $-2.16 | $-6.85 | $-4.49 | $-5.51 | $-0.20 | $-0.20 | $-0.23 | $-0.27 | $-0.30 | $-0.31 | $-0.34 | |
| EPS (Diluted) | $-0.25 | $-0.26 | $-2.28 | $-0.85 | $-1.24 | $-2.16 | $-6.85 | $-4.49 | $-5.51 | $-0.20 | $-0.20 | $-0.23 | $-0.27 | $-0.30 | $-0.31 | $-0.34 | |
| Shares (Basic) | 19,467,091 | 19,467,114 | · | 4,537,683 | 4,119,153 | 2,575,325 | · | 1,577,363 | 1,566,951 | 43,287,325 | · | 31,545,783 | 28,472,346 | 24,732,580 | · | 21,661,544 | |
| Shares (Diluted) | 19,467,091 | 19,467,114 | · | 4,537,683 | 4,119,153 | 2,575,325 | · | 1,577,363 | 1,566,951 | 43,287,325 | · | 31,545,783 | 28,472,346 | 24,732,580 | · | 21,661,544 | |
| EBITDA | $-5M | $-5M | · | $-4M | $-5M | $-6M | · | $-7M | $-9M | $-9M | · | $-7M | $-8M | $-8M | · | $-7M |
资产负债表
| 指标 | 趋势 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $18M | $22M | $27M | $11M | $13M | $12M | $11M | $4M | $10M | $13M | $21M | $13M | $17M | $11M | $18M | $28M | |
| Prepaid Expense | $540.0K | $721.0K | $788.0K | $1M | $515.0K | $837.0K | $1M | $3M | $2M | $3M | $3M | $4M | $2M | $4M | $4M | $2M | |
| Other Current Assets | $364.0K | $395.0K | $259.0K | $346.0K | $367.0K | $427.0K | $298.0K | $177.0K | $529.0K | $539.0K | $270.0K | $262.0K | $277.0K | $601.0K | $232.0K | · | |
| Current Assets | $18M | $23M | $28M | $12M | $14M | $13M | $13M | $7M | $13M | · | $25M | $17M | $19M | $14M | $22M | $30M | |
| PP&E (Net) | $2M | $2M | $2M | $2M | $2M | $3M | $3M | $3M | $3M | $3M | $4M | $4M | $4M | $4M | $4M | $350.0K | |
| Accum. Depreciation | $4M | $3M | $3M | $3M | $3M | $3M | $2M | $2M | $2M | $2M | $1M | $1M | $807.0K | $564.0K | $321.0K | $417.0K | |
| Other Non-current Assets | $102.0K | $129.0K | $146.0K | $169.0K | $275.0K | $275.0K | $275.0K | $324.0K | $320.0K | · | $255.0K | $255.0K | $255.0K | $255.0K | $255.0K | $231.0K | |
| Total Assets | $22M | $26M | $32M | $17M | $19M | $20M | $21M | $16M | $22M | · | $34M | $26M | $30M | $25M | $33M | $38M | |
| Accounts Payable | $444.0K | $449.0K | $309.0K | $204.0K | $379.0K | $575.0K | $389.0K | $1M | $1M | · | $924.0K | $748.0K | $585.0K | $870.0K | $2M | $1M | |
| Accrued Liabilities | $761.0K | $681.0K | $2M | $418.0K | $635.0K | $1M | $1M | $769.0K | $2M | $895.0K | $3M | $2M | $2M | $1M | $2M | $3M | |
| Current Liabilities | $2M | $2M | $3M | $2M | $2M | $3M | $3M | $4M | $5M | · | $5M | $5M | $4M | $4M | $6M | $5M | |
| Capital Leases | $1M | $1M | $2M | $2M | $2M | $3M | $3M | $3M | $4M | $4M | $3M | $3M | $3M | $3M | $4M | $4M | |
| Total Liabilities | $3M | $3M | $5M | $4M | $4M | $6M | $6M | $7M | $9M | · | $9M | $8M | $8M | $8M | $10M | $9M | |
| Common Stock | $10.0K | $10.0K | $10.0K | $10.0K | $10.0K | $8.0K | $7.0K | $5.0K | $5.0K | · | $4.0K | $4.0K | $4.0K | $3.0K | $3.0K | $3.0K | |
| Paid-in Capital | $169M | $169M | $169M | $149M | $148M | $141M | $136M | $124M | $122M | · | $116M | $101M | $98M | $86M | $84M | $83M | |
| Retained Earnings | $-151M | $-146M | $-141M | $-136M | $-132M | $-127M | $-122M | $-115M | $-108M | · | $-91M | $-84M | $-76M | $-69M | $-61M | $-53M | |
| Stockholders' Equity | $18M | $23M | $28M | $13M | $15M | $14M | $14M | $9M | $14M | $18M | $25M | $18M | $22M | $17M | $23M | $30M | |
| Liabilities + Equity | $22M | $26M | $32M | $17M | $19M | $20M | $21M | $16M | $22M | · | $34M | $26M | $30M | $25M | $33M | $38M | |
| Shares Outstanding | 9,853,121 | 9,847,089 | 9,766,132 | 4,589,196 | 4,078,139 | 81,258,763 | 2,416,066 | 46,786,948 | 46,434,656 | · | 43,287,325 | 31,975,929 | 30,606,119 | 24,960,869 | 24,545,157 | 24,502,157 |
现金流
| 指标 | 趋势 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock-based Comp | $352.0K | $401.0K | $711.0K | $692.0K | $955.0K | $831.0K | $825.0K | $2M | $1M | $1M | $1M | $1M | $1M | $859.0K | $922.0K | $897.0K | |
| Operating Cash Flow | $-4M | $-5M | $-2M | $-4M | $-4M | $-3M | $-4M | $-6M | $-6M | $-8M | $-5M | $-6M | $-5M | $-7M | $-8M | $-6M | |
| CapEx | · | · | · | $0 | $0 | $0 | · | $0 | $21.0K | $50.0K | · | $0 | $36.0K | $371.0K | · | $39.0K | |
| Investing Cash Flow | $-233.0K | $-9.0K | $0 | $0 | $0 | $0 | $-33.0K | $0 | $-83.0K | $-71.0K | $-72.0K | $-77.0K | $-22.0K | $-429.0K | $-1M | $-2M | |
| Stock Issued | $0 | $0 | $102.0K | $1M | $4M | $4M | $4M | $-4M | $4M | $0 | $63.0K | $2M | $12M | $722.0K | $9M | $0 | |
| Net Stock Activity | · | $0 | · | · | · | $4M | · | · | · | $0 | · | · | · | · | · | · | |
| Financing Cash Flow | $-51.0K | $-195.0K | $18M | $989.0K | $5M | $4M | $11M | $-105.0K | $3M | $-277.0K | $13M | $2M | $11M | $547.0K | $-253.0K | $9M | |
| Net Change in Cash | $-4M | $-5M | $16M | $-3M | $1M | $771.0K | $7M | $-6M | $-3M | $-8M | $8M | $-4M | $6M | $-7M | $-9M | $2M | |
| Free Cash Flow | · | · | · | · | · | $-3M | · | · | · | $-8M | · | · | · | $-8M | · | · |
盈利能力
| 指标 | 趋势 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROA | -23.3% | -22.1% | · | -23.5% | -24.3% | -24.9% | · | -33.6% | -33.1% | · | · | -22.2% | -25.4% | -24.6% | · | -17.3% | |
| ROE | -28.5% | -27.8% | · | -35.4% | -35.3% | -35.4% | · | -53.8% | -48.7% | -49.9% | · | -30.3% | -31.9% | -30.3% | · | -20.4% |
流动性与偿付能力
| 指标 | 趋势 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 8.2 | 10.5 | · | 6.9 | 7.0 | 4.3 | · | 1.8 | 2.7 | · | · | 3.5 | 5.1 | 3.8 | · | 6.1 | |
| Quick Ratio | 8.0 | 10.2 | · | 6.3 | 6.8 | 4.0 | · | 1.1 | 2.1 | · | · | 2.7 | 4.5 | 2.9 | · | 5.6 |
每股
| 指标 | 趋势 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | $1.86 | $2.31 | · | $2.87 | $3.74 | $0.17 | · | $0.18 | $0.29 | · | · | $0.56 | $0.71 | $0.67 | · | $1.21 | |
| Cash Flow / Share | · | $-0.25 | · | · | · | $-0.04 | · | · | · | $-0.18 | · | · | · | $-0.30 | · | · | |
| Cash / Share | $1.82 | $2.23 | · | $2.33 | $3.24 | $0.15 | · | $0.09 | $0.22 | · | · | $0.40 | $0.56 | $0.44 | · | $1.13 | |
| EPS (TTM) | $-3.64 | $-4.63 | · | $-11.10 | $-14.74 | $-19.01 | · | $-10.40 | $-6.14 | $-0.90 | · | $-1.11 | $-1.22 | $-1.33 | · | $-1.26 |
估值 (TTM)
| 指标 | 趋势 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income TTM | $-19M | $-19M | · | $-21M | $-24M | $-27M | · | $-32M | $-32M | $-31M | · | $-30M | $-30M | $-30M | · | $-27M | |
| Market Cap | $14M | $15M | · | $10M | $9M | $405M | · | $379M | $1.18B | · | · | $998M | $1.41B | $973M | · | $1.48B | |
| P/E | -0.4 | -0.3 | · | -0.2 | -0.1 | -0.3 | · | -0.8 | -4.1 | -39.3 | · | -28.1 | -37.9 | -29.3 | · | -48.1 | |
| P/B | 0.8 | 0.6 | · | 0.8 | 0.6 | 29.2 | · | 44.1 | 86.6 | · | · | 56.2 | 64.9 | 58.0 | · | 50.2 | |
| P / Tangible Book | 0.8 | 0.6 | · | 0.8 | 0.6 | 29.2 | · | 44.1 | 86.6 | · | · | 56.2 | 64.9 | 58.0 | · | 50.2 | |
| P / Cash Flow | · | -2.9 | · | · | · | -129.6 | · | · | · | · | · | · | · | -130.9 | · | · | |
| Earnings Yield | -258.2% | -312.8% | · | -511.5% | -705.3% | -381.7% | · | -128.4% | -24.2% | -2.5% | · | -3.6% | -2.6% | -3.4% | · | -2.1% |
最近期在左侧 · 空值显示为 ·
财务报表 损益表、资产负债表、现金流量表 — 年度，近5年
| 指标 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| 净收入 | $-19M | $-30M | $-30M | $-29M | $-15M |
| 稀释后每股收益 (EPS) | $-4.44 | $-17.05 | $-1.00 | $-1.36 | $-1.47 |
| 指标 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| 流动比率 | 8.8 | · | 4.6 | 3.8 | 17.3 |
| 速动比率 | 8.6 | · | 3.9 | 3.1 | 16.4 |
此报表无数据
基本面数据不足，尚无法生成此报表。
机构持有人 (13F) 23 家申报者 · $5.5M 总计 · 截至 2026年6月30日
在其季度SEC表格13F中报告持有此股票的机构。仅限多头头寸；单个申报人可能因单独的期权腿而出现两次。 大的抵消性看跌/看涨腿通常反映做市或对冲库存，而非方向性判断。
持有人
23
持有价值
$5.5M
新仓位
3
已退出持仓
1
机构活动 — Q2 2026 与上一季度对比
| 新仓位 | 已退出持仓 | 增加 | 减少 | 净股数变动 |
|---|---|---|---|---|
| 3 (-1 与上一季度对比) | 1 (-3 与上一季度对比) | 5 (+2 与上一季度对比) | 3 (-3 与上一季度对比) | +37K |
与Q1 2026对比。 SEC 13F表格的提交截止日期是季度末后45天，外加少量延迟提交的缓冲期——在此窗口期内的季度将被跳过，优先显示最近一个已完整报告的季度对。
激进投资者及 5%+ 股东 2 持仓
提交了 SEC Schedule 13D 的投资者 — 持有超过 5% 的受益所有权，意图影响发行人（激进股东持股、董事会活动、并购）。每一行显示该申报人持仓的最新已知状态。
| 申报人 | 已申报 | 持股 | 状态 | 目的 | 申报 |
|---|---|---|---|---|---|
| EMILY FAIRBAIRN, Malcom Fairbairn, Malcom and Emily Fairbairn 2010 CRUT ×2 申报 | 2026年5月29日 | 2.20% | 修订 | · | SEC |
| BIOS Fund II, LP, BIOS Fund II QP, LP, BIOS Fund II NT, LP, BIOS Incysus Co-Invest I, LP, BIOS Fund III, LP, BIOS Fund III QP, LP, BIOS Fund III NT, LP, Bios Clinical Opportunity Fund, LP, BP Directors, LP, Bios Equity Partners, LP, Bios Equity Partners II, LP, BIOS Equity Partners III, LP, Bios Equity COF, LP, Cavu Management, LP, BIOS Capital Management, LP, Cavu Advisors, LLC, BIOS Advisors GP, LLC, Kreis Leslie W., Fletcher Aaron G.L. ×5 申报 | 2025年12月29日 | 2.90% | 修订 | · | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
公司内部人士 12 位内幕人士 · 5 位高管 · 8 位董事
| 内部人士 | 角色 | 上次活动 | 持股数量 | 买入 12个月 | 卖出 12个月 | 净额 12个月 |
|---|---|---|---|---|---|---|
| William Tai-Wei Ho | CEO | 2026年5月9日 A | 121168 | 0 | 0 | $0 |
| McCall Patrick | CHIEF FINANCIAL OFFICER | 2026年5月9日 A | 9482 | 0 | 0 | $0 |
| Kate Rochlin | President and COO | 2026年5月9日 A | 9085 | 0 | 0 | $0 |
| Lawrence Lamb | EVP and CSO | 2026年5月9日 A | 101369 | 0 | 0 | $0 |
| Trishna Goswami | Chief Medical Officer | 2024年9月4日 A | 6729 | 0 | 0 | $0 |
| Jeremy R. Graff | 董事 | 2026年5月9日 A | 4549 | 0 | 0 | $0 |
| Luba Greenwood | 董事 | 2026年5月9日 A | 7826 | 0 | 0 | $0 |
| Corinne Epperly | 董事 | 2026年5月9日 A | 81967 | 0 | 0 | $0 |
| EMILY FAIRBAIRN | 董事 | 2026年5月9日 A | 724637 | 0 | 0 | $0 |
| Peter C. Brandt | 董事 | 2026年5月9日 A | 95181 | 0 | 0 | $0 |
| Alan S. Roemer | 董事 | 2025年12月22日 A | 49514 | 0 | 0 | $0 |
| Travis Whitfill | 董事 | 2024年12月19日 A | · | 0 | 0 | $0 |
来自SEC表格3/4/5申报的内部人士；净额=仅公开市场买卖
ETF持仓 由 2 只交易所交易基金持有
权重仅反映直接股权持仓（N-PORT）；杠杆基金或基于衍生品的基金可能持有未显示的额外掉期敞口。
INAB 分析师共识 看涨和看跌分析师观点、12个月价格目标、上涨空间
评级 · 10 位分析师
买入
中位数目标
$6.00
+328.6%
2 20.0%
强烈买入
7 70.0%
买入
1 10.0%
持有
0 0.0%
卖出
0 0.0%
强烈卖出
12个月价格目标
3 位分析师 · 2026-09-30平均目标 $7.00 +400.0%
← 低于所有目标
当前价格 $1.40
最低$5.00
平均值$7.00
最高$10.00
同行比较（GICS 子行业） 关键指标与行业同行对比
财年依据，价格截至各公司上一个财年末收盘价。
我的指标 您的个人关注列表 — 来自完整基本面的选定行
选择对您重要的指标 — 点击上方完整基本面中任意行的 + 号。
您的选择已保存，并会跟随您浏览所有股票。
来源：SEC 10-Q 于 八月 6, 2026 申报